Validating cancer drug targets

A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as |[lsquo]|validated|[rsquo]| before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

, , , , , , &

To read this article in full you may need to log in, make a payment or gain access through a site license (see right).